833 related articles for article (PubMed ID: 12095556)
1. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
2. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
Kupelian PA; Willoughby TR
Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
[TBL] [Abstract][Full Text] [Related]
3. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.
Kupelian PA; Reddy CA; Klein EA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):988-93. PubMed ID: 11704322
[TBL] [Abstract][Full Text] [Related]
4. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?
Kupelian PA; Reddy CA; Carlson TP; Willoughby TR
Cancer J; 2002; 8(1):62-6. PubMed ID: 11895204
[TBL] [Abstract][Full Text] [Related]
5. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland.
Mohan DS; Kupelian PA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):575-80. PubMed ID: 10701736
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
7. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison.
Perez CA; Michalski JM; Purdy JA; Wasserman TH; Williams K; Lockett MA
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):629-37. PubMed ID: 10837945
[TBL] [Abstract][Full Text] [Related]
9. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients.
Zelefsky MJ; Fuks Z; Hunt M; Yamada Y; Marion C; Ling CC; Amols H; Venkatraman ES; Leibel SA
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1111-6. PubMed ID: 12128109
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
Perez CA; Michalski JM; Mansur D; Lockett MA
Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700
[TBL] [Abstract][Full Text] [Related]
11. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
12. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.
Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R
Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899
[TBL] [Abstract][Full Text] [Related]
13. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
[TBL] [Abstract][Full Text] [Related]
15. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
[TBL] [Abstract][Full Text] [Related]
16. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity.
Pollack A; Zagars GK; Starkschall G; Childress CH; Kopplin S; Boyer AL; Rosen II
Int J Radiat Oncol Biol Phys; 1996 Feb; 34(3):555-64. PubMed ID: 8621278
[TBL] [Abstract][Full Text] [Related]
17. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).
Ryu JK; Winter K; Michalski JM; Purdy JA; Markoe AM; Earle JD; Perez CA; Roach M; Sandler HM; Pollack A; Cox JD
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1036-46. PubMed ID: 12419429
[TBL] [Abstract][Full Text] [Related]
18. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
19. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
